Key facts
- This page summarizes Bruce Booth's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2023, 15:53.
Bruce Booth - 11 Jan 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)
- Reporting relationship
- Director
- Issuer ticker
- KYMR
- Reported as of
- 11 Jan 2023
- Net transaction value
- -$3,821,739
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2023, 15:53:09 UTC
- Prior SEC filing
- 16 Dec 2022
- Next SEC filing
- 03 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ommer Chohan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bruce Booth filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 13 Jan 2023.
Change
- Previous filing in this sequence was filed on 16 Dec 2022.
- Current net transaction value: -$3,821,739.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KYMR
transaction
Common Stock
Sale
- Transaction value
- $649,623
- Shares
- -21,683
- Change %
- -0.43%
- Price
- $29.96
- Shares after
- 5,045,242
- Date
- 11 Jan 2023
- Ownership
- See footnote
- Footnotes
- F1, F2, F3
KYMR
transaction
Common Stock
Sale
- Transaction value
- $181,887
- Shares
- -6,071
- Change %
- -0.66%
- Price
- $29.96
- Shares after
- 911,740
- Date
- 11 Jan 2023
- Ownership
- See footnote
- Footnotes
- F1, F2, F4
KYMR
transaction
Common Stock
Sale
- Transaction value
- $2,336,207
- Shares
- -77,128
- Change %
- -1.5%
- Price
- $30.29
- Shares after
- 4,968,114
- Date
- 12 Jan 2023
- Ownership
- See footnote
- Footnotes
- F1, F3, F5
KYMR
transaction
Common Stock
Sale
- Transaction value
- $654,022
- Shares
- -21,592
- Change %
- -2.4%
- Price
- $30.29
- Shares after
- 890,148
- Date
- 12 Jan 2023
- Ownership
- See footnote
- Footnotes
- F1, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Shares were sold pursuant to a Rule 10b5-1 trading plan.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $29.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (5).
Footnote F3
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
Footnote F4
The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.65 inclusive.